.jpg?format=webp&width=780)
The study aimed to investigate the impact of castration status on the incidence of docetaxel‐related AE in metastatic prostate cancer (mPCa) patients. Castration status did not affect the risk of severe neutropenia or FN in mPCa patients treated with docetaxel regardless of the disease state. Failure to provide primary prophylaxis and advanced patient age are independent risk factors of severe neutropenia; while patients with poor PS are more likely to develop FN. These findings may help guide the clinical decision‐making for proper candidate selection of docetaxel treatment.
Like
Save
Share